Artwork
iconShare
 
Manage episode 504222988 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.

  • Lymphomas
    • DLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCT
    • FL: Tisa-cel (ELARA), axi-cel (ZUMA-5)
    • MZL: Liso-cel (TRANSCEND FL)
    • MCL: Real-world outcomes post brexu-cel
    • CLL: Liso-cel (TRANSCEND CLL 004)
  • Multiple Myeloma
    • Cilta-cel (CARTITUDE-1)
    • Anito-cel (iMMagine-1)
    • GC012F
    • Arlo-cel
    • BMS-986453
    • TriPRIL

Presenters:

Brad Kahl, MD
Professor of Medicine
Washington University
St Louis, Missouri

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/3ViR62V


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

  continue reading

211 episodes